Fineline Cube

Follow:
14398 Articles
Bristol-Myers Squibb's Dual Immunotherapy Achieves Global First Approval for MSI-H/dMMR CRC in China
CompanyDrug

BMS’s Dual Immunotherapy Achieves Global First Approval for MSI-H/dMMR CRC in China

Sichuan Biokin Pharmaceutical Gets FDA Approval for CD33-Targeting ADC in Acute Myeloid Leukemia
CompanyDrug

Sichuan Biokin Pharmaceutical Gets FDA Approval for CD33-Targeting ADC in Acute Myeloid Leukemia

iRegene Therapeutics Secures Over USD 14 Million in Series B Financing to Advance Cell Therapies
CompanyDeals

iRegene Therapeutics Secures Over USD 14 Million in Series B Financing to Advance Cell Therapies

BrightGene's BGM0504 Shows Promise in Phase II Obesity Study Without Diabetes
CompanyDrug

BrightGene’s BGM0504 Shows Promise in Phase II Obesity Study Without Diabetes

Dizal Pharmaceutical's Sunvozertinib Earns Breakthrough Designation for NSCLC from China's NMPA
CompanyDrug

Dizal Pharmaceutical’s Sunvozertinib Earns Breakthrough Designation for NSCLC from China’s NMPA

NMPA Sets Forthcoming Guidelines for Domestic Drug Refiling Procedures
Policy / Regulatory

NMPA Sets Forthcoming Guidelines for Domestic Drug Refiling Procedures

Huawei Partners with Medical University Hospital to Boost Healthcare Innovation
CompanyDeals

Huawei Partners with Medical University Hospital to Boost Healthcare Innovation

Reforgene Medicine’s Gene Editing Therapy RM-101 Clears IND Hurdle for Usher Syndrome Treatment
CompanyDrug

Reforgene Medicine’s Gene Editing Therapy RM-101 Clears IND Hurdle for Usher Syndrome Treatment

Akeso Biopharma Secures USD 250 Million in Share Placement, Bolstering Drug Development War chest
CompanyDeals

Akeso Biopharma Secures USD 250 Million in Share Placement, Bolstering Drug Development War chest

Jiangsu Hengrui’s RGL-193 Receives NMPA Greenlight for Parkinson’s Disease Clinical Study
CompanyDrug

Jiangsu Hengrui’s RGL-193 Receives NMPA Greenlight for Parkinson’s Disease Clinical Study

Novartis’s Brolucizumab Accepted for Review by China’s CDE for Potential DME Treatment
CompanyDrug

Novartis’s Brolucizumab Accepted for Review by China’s CDE for Potential DME Treatment

Pfizer’s Talzenna Combo Shows Improved Survival in mCRPC Patients, According to TALAPRO-2 Study
CompanyDrug

Pfizer’s Talzenna Combo Shows Improved Survival in mCRPC Patients, According to TALAPRO-2 Study